Nippon Shokubai's Health & Medical Business division operates as a CDMO specializing in oligonucleotide and peptide API manufacturing. The company has two oligonucleotide synthesis/purification lines and one peptide line, making it one of Japan's largest manufacturers in this sector. A tenfold GMP capacity expansion (several kg/batch) is planned for 2027 to meet growing global demand for nucleic acid drug APIs.
oligonucleotide API synthesis and purification, peptide API manufacturing, nucleic acid drug development, GMP-compliant API production
1 site worldwide
No reviews available yet.
No documents available.